Review



random blood glucose 16 7 mmol l rhadamts13  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems random blood glucose 16 7 mmol l rhadamts13
    ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or <t>rhADAMTS13</t> (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.
    Random Blood Glucose 16 7 Mmol L Rhadamts13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/random+blood+glucose+16+7+mmol+l+rhadamts13/Recombinant+Human+ADAMTS13+Protein%2C+CF/pmc13037144-108-11-18
    Average 94 stars, based on 35 article reviews
    random blood glucose 16 7 mmol l rhadamts13 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway"

    Article Title: ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway

    Journal: Renal Failure

    doi: 10.1080/0886022X.2026.2646089

    ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or rhADAMTS13 (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.
    Figure Legend Snippet: ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or rhADAMTS13 (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.

    Techniques Used: In Vivo, Control, Injection, Immunohistochemical staining, Staining, Expressing

    Related Articles

    Saline:

    Article Title: ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway
    Article Snippet: One week after the last time of STZ injection, blood glucose levels were measured from tail-vein blood samples using the Accu-Chek Aviva glucometer (Roche Diabetes Care, Mannheim, Germany). .. Hyperglycemia was defined as a fasting blood glucose ≥11.1 mmol/L or random blood glucose ≥16.7 mmol/L. rhADAMTS13 (4245-AD, R&D Systems, Minneapolis, MN) was dissolved in saline and administered to mice via tail vein injections. ..

    Article Title: ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway
    Article Snippet: Since estrogen is the main sex hormone in females and is thought to have renoprotective effects, we chose male mice for the research in this study [27]. ten- to twelve-week-old C57bL/6 male mice with similar body weights were randomly divided into the following four groups: control group, rhadaMtS13 treatment group, dN group, dN + rhadaMtS13 treatment group, with 5 mice in each group. the mice that received an intraperitoneal injection of citrate buffer (0.1 M, pH 4.5) for five consecutive days were designated the control group. the mice that received an intraperitoneal injection of low-dose streptozotocin (StZ, 50 mg/kg/day) (S0130, Sigma, St. Louis, Mo) for five consecutive days were designated the dN group. one week after the last time of StZ injection, blood glucose levels were measured from tail-vein blood samples using the accu-Chek aviva glucometer (roche diabetes Care, Mannheim, Germany). .. Hyperglycemia was defined as a fasting blood glucose ≥11.1 mmol/L or random blood glucose ≥16.7 mmol/L. rhadaMtS13 (4245-ad, r&d Systems, Minneapolis, MN) was dissolved in saline and administered to mice via tail vein injections. the mice that were injected with 2.6 μg/kg rhadaMtS13 for seven consecutive days after citrate buffer or StZ injection were designated the rhadaMtS13 group and dN + rhadaMtS13 group. .. Eight weeks following successful model establishment, mice were anesthetized with 2% isoflurane (r510-22, rWd Life Science Co., Ltd., Shenzhen, China) and euthanized by cervical dislocation, followed by collection of blood, urine, renal tissue, and aortic samples. the animal experimental design is illustrated in Figure 1(a). the animal experimental design is illustrated in Figure 2(a).

    Injection:

    Article Title: ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway
    Article Snippet: Since estrogen is the main sex hormone in females and is thought to have renoprotective effects, we chose male mice for the research in this study [27]. ten- to twelve-week-old C57bL/6 male mice with similar body weights were randomly divided into the following four groups: control group, rhadaMtS13 treatment group, dN group, dN + rhadaMtS13 treatment group, with 5 mice in each group. the mice that received an intraperitoneal injection of citrate buffer (0.1 M, pH 4.5) for five consecutive days were designated the control group. the mice that received an intraperitoneal injection of low-dose streptozotocin (StZ, 50 mg/kg/day) (S0130, Sigma, St. Louis, Mo) for five consecutive days were designated the dN group. one week after the last time of StZ injection, blood glucose levels were measured from tail-vein blood samples using the accu-Chek aviva glucometer (roche diabetes Care, Mannheim, Germany). .. Hyperglycemia was defined as a fasting blood glucose ≥11.1 mmol/L or random blood glucose ≥16.7 mmol/L. rhadaMtS13 (4245-ad, r&d Systems, Minneapolis, MN) was dissolved in saline and administered to mice via tail vein injections. the mice that were injected with 2.6 μg/kg rhadaMtS13 for seven consecutive days after citrate buffer or StZ injection were designated the rhadaMtS13 group and dN + rhadaMtS13 group. .. Eight weeks following successful model establishment, mice were anesthetized with 2% isoflurane (r510-22, rWd Life Science Co., Ltd., Shenzhen, China) and euthanized by cervical dislocation, followed by collection of blood, urine, renal tissue, and aortic samples. the animal experimental design is illustrated in Figure 1(a). the animal experimental design is illustrated in Figure 2(a).



    Similar Products

    random blood glucose 16 7 mmol l rhadamts13  (R&D Systems)
    94
    R&D Systems random blood glucose 16 7 mmol l rhadamts13
    ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or <t>rhADAMTS13</t> (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.
    Random Blood Glucose 16 7 Mmol L Rhadamts13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/random+blood+glucose+16+7+mmol+l+rhadamts13/Recombinant+Human+ADAMTS13+Protein%2C+CF/pmc13037144-108-11-18
    Average 94 stars, based on 1 article reviews
    random blood glucose 16 7 mmol l rhadamts13 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or rhADAMTS13 (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.

    Journal: Renal Failure

    Article Title: ADAMTS13 ameliorates diabetic nephropathy by Nrf2/GPX4/eNOS signaling pathway

    doi: 10.1080/0886022X.2026.2646089

    Figure Lengend Snippet: ADAMTS13 maintained renal function and attenuated renal fibrosis in vivo . Control mice were treated with vehicle (Control). The STZ-treated mice were infused with vehicle (DN) or rhADAMTS13 (DN + rhADAMTS13). rhADAMTS13 (2.6 ug/kg body weight) was injected into the tail vein daily for the subsequent 7 d. (A) The workflow of animal experiments. (B) Representative renal immunohistochemical staining of ADAMTS13 in the kidney. Scale Bar: 30 μm. (C) Representative renal morphological images of mice were shown. Hematoxylin-Eosin (HE), Masson’s trichrome and Periodic Acid-Schiff (PAS) staining of kidney slices. Scale Bar: 30 μm. (D) Body weight. (E) Serum glucose. (F) BUN. (G) Scr. (H) Urinary volume. (I) Proteinuria. (J) Urinary KIM-1. (K) Renal KIM-1 mRNA expression. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif member 13; DN: diabetic nephropathy; BUN: blood urea nitrogen; Scr: serum creatinine; KIM-1: kidney injury molecule-1. Results were presented as mean ± SEM. N = 5, ** P < 0.01, *** P < 0.001, one-way ANOVA followed by Tukey’s post hoc test.

    Article Snippet: Hyperglycemia was defined as a fasting blood glucose ≥11.1 mmol/L or random blood glucose ≥16.7 mmol/L. rhADAMTS13 (4245-AD, R&D Systems, Minneapolis, MN) was dissolved in saline and administered to mice via tail vein injections.

    Techniques: In Vivo, Control, Injection, Immunohistochemical staining, Staining, Expressing